4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:原厂直采,平行进口,授权代理(蚂蚁淘为您服务)
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > Sphingomyelin > asuragen/QuantideX® qPCR BCR-ABL minor Kit (RUO)/60/49640
商品详细asuragen/QuantideX® qPCR BCR-ABL minor Kit (RUO)/60/49640
asuragen/QuantideX® qPCR BCR-ABL minor Kit (RUO)/60/49640
asuragen/QuantideX® qPCR BCR-ABL minor Kit (RUO)/60/49640
商品编号: 49640
品牌: asuragen
市场价: ¥0.00
美元价: 0.00
产地: 美国(厂家直采)
公司:
产品分类:
公司分类: Sphingomyelin
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

QuantideX® qPCR BCR-ABL minor Kit (RUO)

BCR-ABL blood cancer cellsThe QuantideX® qPCR BCR-ABL minor Kit (RUO) is a clinical research tool enabling ultra-sensitive and precise detection of BCR-ABL1 minor fusion transcripts (e1a2) from whole blood specimens. Building on the simple workflow and best-in-class sensitivity established with the FDA-cleared QuantideX® qPCR BCR-ABL IS Kit, the minor Kit allows labs and clinical researchers to examine the biology of disease for this very rare but distinct leukemic variant with unprecedented ease.

Features & Benefits

The QuantideX qPCR BCR-ABL minor Kit (RUO) delivers high performance through unmatched sensitivity and optimized laboratory efficiency.

Reduced ComplexityEase-of-data analysis and reporting:

  • Leverages the QuantideX® qPCR BCR-ABL IS Kit workflow concept for streamlined implementation
  • Included software provides automated calculation of BCR-ABL1/ABL1 % ratio and eliminates the need for manual calculation

Optimized WorkflowValuable operator hands-on time has been significantly reduced through:

  • Multiplexed design amplifies and detects both fusion and control gene in the same reaction
  • All-inclusive reagents sourced and quality controlled together from a single vendor
  • Pre-mixed reagents allow fewer pipetting steps in mastermix preparation

Quality PerformanceDetecting BCR-ABL1 minor transcripts robustly and reliably with a highly sensitive assay:

  • Ultra-sensitive Limit of Detection (LOD): Log reduction of 4.61 (0.0025% ratio)
  • Increased analytical sensitivity without compromising analytical specificity: incorporates Limit of Blank (LOB) to prevent miscalling of non-leukemic low positives
  • Armored RNA®-based standards provide true RNA quantification

Analytical Characteristics

  • Reproducible: Proven sensitivity based on rigorous testing criterion (Table 1)
  • Precise: Minimal variability across entire dynamic range of BCR-ABL1/ABL1 % ratios (Table 2)
  • Streamlined: Multiplexed design yields workflow and cost efficiencies (Figure 1)

Proven Sensitivity Based on Rigorous Testing CriterionTable 1: LOD as determined by CLSI EP17-A2 guidelines by testing human RNA and cell line dilutions spanning lots, batch runs, days, operators and instruments.

Minimal Variability across Entire Dynamic Range

Table 2: Assay precision determined by testing 4 different log reduction (LR) levels in human RNA, using 2 operators and 8 runs for a total of 192 data points.

Multiplexed Design Yields Workflow and Cost Efficiency  

Figure 1: Comparison of a plate layout for 8 sample run on Asuragen plate (left) and an alternate non-multiplex assay (right): 19 reactions for Asuragen setup vs. 52 reactions on a non-multiplex assay setup

Ordering

Product NameNumber of ReactionsCatalog Number
QuantideX® qPCR BCR-ABL minor Kit (RUO)6049637

T 512.681.5200 or 877.777.1874 F 512.681.5202 E orders@asuragen.com

View Sales Contacts

QuantideX® qPCR BCR-ABL minor Kit

The BCR-ABL1 minor breakpoint (e1a2) constitutes a rare but distinct leukemic variant and accurate detection and quantitation of these fusion transcripts are paramount to improving outcomes for all chronic myeloid leukemia (CML) patients. The QuantideX® qPCR BCR-ABL minor Kit, an in vitro diagnostic (IVD) assay, enables ultra-sensitive detection of BCR-ABL1 minor fusion transcripts from whole blood specimens.

Features & Benefits

The QuantideX qPCR BCR-ABL minor Kit marries improved efficiency with unprecedented sensitivity, empowering labs to assess the deepest molecular responses in patients harboring the minor breakpoint with the ease-of-use they’ve come to expect from Asuragen.

Reduced ComplexityEase-of-data analysis and reporting:

  • Shares a common workflow with the QuantideX® qPCR BCR-ABL IS Kit to reduce training burden and streamline test implementation
  • Included software provides automated calculation of BCR-ABL1/ABL1 % ratio and the ability to report BCR-ABL Major on both the International Scale (IS) and copy number*

Optimized WorkflowValuable operator hands-on time has been significantly reduced through:

  • Multiplexed design amplifies and detects both fusion and control gene in the same reaction
  • All necessary RT and qPCR reagents sourced and quality controlled together from a single vendor
  • Pre-mixed reagents allow fewer pipetting steps in mastermix preparation

Quality PerformanceDetecting BCR-ABL1 minor transcripts robustly and reliably with a highly sensitive assay:

  • Ultra-sensitive Limit of Detection (LOD): Log reduction of 4.61 (0.0025% ratio)
  • Increased analytical sensitivity without compromising analytical specificity: incorporates Limit of Blank (LOB) to prevent miscalling of non-leukemic low positives
  • Armored RNA®-based standards provide true RNA quantification

Download Brochure

Analytical Characteristics

  • Reproducible: Proven sensitivity based on rigorous testing criterion (Table 1)
  • Precise: Minimal variability across entire dynamic range of BCR-ABL1/ABL1 % ratios (Table 2)
  • Streamlined: Multiplexed design yields workflow and cost efficiencies (Figure 1)

Proven Sensitivity Based on Rigorous Testing CriterionTable 1: LOD as determined by CLSI EP17-A2 guidelines by testing human RNA and cell line dilutions spanning lots, batch runs, days, operators and instruments.

Minimal Variability across Entire Dynamic Range

Table 2: Assay precision determined by testing 4 different log reduction (LR) levels in human RNA, using 2 operators and 8 runs for a total of 192 data points.

Multiplexed Design Yields Workflow and Cost Efficiency  

Figure 1: Comparison of a plate layout for 8 sample run on Asuragen plate (left) and an alternate non-multiplex assay (right): 19 reactions for Asuragen setup vs. 52 reactions on a non-multiplex assay setup

Ordering

Product NameNumber of ReactionsCatalog Number
QuantideX® qPCR BCR-ABL minor Kit6049640

T +1 512.681.5200 or +1 877.777.1874 F +1 512.681.5202 E orders@asuragen.com

View Sales Contacts
品牌介绍
asuragen的QuantideX®qPCR BCR-ABL次要试剂盒(RUO)BCR-ABL血液癌细胞该QuantideX ® qPCR的BCR-ABL轻微套件(RUO)是临床研究工具,使超灵敏和精确的检测BCR-ABL1从全血标本轻微融合基因(e1a2)。在简单的工作流程和最佳的一流的灵敏度与确立的全面建设FDA批准QuantideX ® qPCR的BCR-ABL IS套装,小工具允许实验室和临床研究人员研究疾病的生物学这一非常罕见的,但不同白血病变异与前所未有的轻松。特点与优势分析特性订购方式特点与优势QuantideX qPCR BCR-ABL次要试剂盒(RUO)通过无与伦比的灵敏度和优化的实验室效率提供了高性能。降低复杂性易于数据分析和报告:充分利用了QuantideX ® qPCR的BCR-ABL IS套装的工作流程概念简化实施随附的软件可自动计算BCR-ABL1 / ABL1%比率,无需手动计算优化的工作流程通过以下方式大大减少了宝贵的操作员动手时间:多重设计可在同一反应中扩增并检测融合基因和对照基因单一供应商共同采购和控制质量的全包试剂预混试剂可减少预混液的移液步骤通过高灵敏度的检测方法可靠,可靠地检测 BCR-ABL1次要转录本的质量表现:超灵敏的检测下限(LOD):对数减少4.61(比率为0.0025%)在不影响分析特异性的情况下提高分析灵敏度:结合了空白限度(LOB)以防止误判非白血病低阳性基于铠装RNA®的标准品可提供真正的RNA定量